OpenAI Offers Free AI Model to Government Agencies for Pandemic Preparedness
OpenAI launched Rosalind Biodefense on May 29, a program providing free access to GPT-Rosalind, a specialized AI model for life sciences, to government agencies, academic institutions, and nonprofit organizations working on pandemic preparedness and biodefense. The company will cover all access costs for approved participants.
The program operates on two tracks. A developer track sponsors vetted teams building epidemiological models, early-detection tools, and screening systems. A government track extends access to select U.S. federal agencies and allied partners for outbreak-response planning, diagnostics, and medical countermeasure development.
Initial partners include Lawrence Livermore National Laboratory, which will pair GPT-Rosalind with supercomputing to design medical countermeasures; Johns Hopkins Applied Physics Laboratory, which is integrating the model into protein-engineering platforms; and the Coalition for Epidemic Preparedness Innovations (CEPI), which plans to apply it to rapid vaccine development against emerging threats including Bundibugyo Ebola.
What GPT-Rosalind Does
GPT-Rosalind is OpenAI's reasoning model for life sciences, first introduced in April 2026 for drug discovery, genomics, and protein research. According to OpenAI's internal benchmarks, it outperforms GPT-5, GPT-5.2, and GPT-5.4 in chemistry, biochemistry, and experiment design.
The model assists researchers with evidence synthesis, hypothesis generation, experiment design, and data analysis. It specializes in reasoning about molecules, proteins, genes, and disease-relevant biology.
This marks the first time OpenAI has offered a specialized model free of charge to government partners at this scale.
Who Can Apply
The developer track targets academic institutions, nonprofits, government-affiliated organizations, and small-to-midsized teams with clear public benefit goals. OpenAI is seeking projects focused on defensive research including literature synthesis, protocol design, model-building, data harmonization, and simulation.
The government track is narrower, extending access to select U.S. government and allied partners with explicit public-health and biodefense missions. Focus areas include early-warning systems, outbreak-response planning, diagnostics, and development of vaccines and therapeutics.
Applications are open worldwide through OpenAI's website. The company will evaluate applications on a rolling basis.
The Strategic Context
OpenAI frames the initiative as "defensive acceleration," arguing that frontier AI should benefit those responsible for biodefense and public-health protection. The company acknowledged that AI carries "massive implications for biosecurity, including the creation of biological weapons."
The launch arrives after President Trump postponed an executive order that would have created a standardized federal review process for the most powerful AI models before release. In the absence of that framework, OpenAI is setting its own terms for early government access in the biological domain.
OpenAI briefed the White House and federal agencies on the program before the public announcement.
What Comes Next
OpenAI plans to expand the initial cohort of partners over time. The company's broader approach includes backing startups building biosecurity tools, engaging outside stakeholders on safety, and developing internal systems to evaluate biological risk from its models.
The program distinguishes OpenAI from competitors' typical enterprise licensing structures. For OpenAI, the effort also deepens relationships with U.S. national security agencies at a time when government AI procurement is accelerating.
AI for Government resources can help professionals understand how agencies are adopting these tools. For those in research roles, AI for Science & Research covers applications across life sciences and biodefense.
Your membership also unlocks:
